CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

398 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-19

Study Completion Date

2018-07-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CCTG 595 is a controlled, open-label, two-arm, randomized (1:1) clinical demonstration project to determine if the use of a text-message based adherence intervention (iTAB) improves retention and adherence to PrEP compared to standard of care (SoC) PrEP delivery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women

NCT02584140

HIV Prevention

COMPLETED PHASE4

Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting

NCT02037594

Human Immunodeficiency Virus (HIV)

COMPLETED NA

PrEP iT! Mobile App Intervention

NCT04509076

Treatment Adherence and Compliance

COMPLETED NA

Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

NCT03086200

Patient Adherence HIV Seronegativity

COMPLETED NA

CCTG 593: Testing and Linkage to Care

NCT01941121

HIV Positive HIV Seronegative

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 400 HIV-uninfected men who have sex with men (MSM)and male to female (M to F) transgender individuals with recent high-risk transmission behavior will be enrolled into the study. Each subject will be followed for up to 48 weeks after enrollment of the last subject. The primary endpoint will be measured at 48 weeks.

All subjects will start PrEP with TDF + FTC fixed dose combination given once daily. Subjects will be randomized (1:1) to either the iTAB text messaging adherence reminder intervention with SoC or the SoC alone arm. Subjects placed into the iTAB intervention arm will receive a personalized, automated texting system to maintain adherence and retention. Both groups will receive access to PrEP in accordance with standardized comprehensive methods of prescribing, risk reduction counseling, adherence counseling, and clinical assessments that include safety monitoring, as well as HIV and STD screening.

TDF 300 mg + FTC 200 mg fixed dose combination will be given orally once daily starting at the baseline visit (month 0) and continued throughout the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patient Adherence HIV Seronegativity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

The purpose of this study is to evaluate a promising method of reinforcing PrEP adherence using text message. In this study, we will hope to learn if text message reminders increase PrEP adherence.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Group 1: PrEP daily, HIV/STI screening, adherence and risk behavior counseling, and safety monitoring Group 2: PrEP daily, HIV/STI screening, adherence and risk behavior counseling, and safety monitoring as well as iTAB text adherence reminders

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care (SoC)

This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.

All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey.

Group Type NO_INTERVENTION

No interventions assigned to this group

SoC + iTab

Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.

Subjects will have visits with the study coordinator to introduce the iTAB texting system.

Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers.

Group Type ACTIVE_COMPARATOR

SoC + iTab

Intervention Type DEVICE

Text messaging reminders to improve adherence to PrEP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SoC + iTab

Text messaging reminders to improve adherence to PrEP

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or transgender M to F who has sex with men.
* Age 18 years or older.
* Subjects must have substantial ongoing risk of acquisition of HIV as evident by one or more of the following:

* Has at least one HIV infected sexual partner for ≥4 weeks.
* No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last 3 months.
* No condom use during anal sex with ≥1 male partner and STI diagnosis during the last 3 months.
* Negative for HIV infection by rapid HIV test and confirmed negative by NAT or other sensitive method such as antibody- antigen test.
* Acceptable laboratory values in the past 30 days:

* Calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula (eCcr (male) in mL/min = \[(140 - age in years) x (lean body weight in kg)\] / (72 x serum creatinine in mg/dL)
* Alanine aminotransferase (ALT) and/ or aspartate aminotransferase (AST) \< 3 x upper limit of normal (ULN)
* Hemoglobin \> 9 g/dL
* Absolute neutrophil count \> 750/ mm3
* Platelets \> 75,000/ mm3

Exclusion Criteria

* Unable to give informed consent.
* Active hepatitis B (positive hepatitis B surface antigen (HBSAg) or HBSAg negative/ HB core antibody positive/ HBV PCR positive).
* Has substantial medical condition, that in the opinion of the investigator would preclude participation, as defined by

* cardiovascular condition that may lead to an increased risk of complication if placed on study drugs.
* gastrointestinal condition that would impair absorption of study drugs.
* neurological or psychiatric condition that would significantly impair the ability to adhere to PrEP.
* calculated GFR \< 60 mL/min.
* alcohol or drug abuse or dependence that would significantly impair the ability to adhere to PrEP (only for those with severe impairment).
* other medical condition that would unacceptably increase the risk of harm from study drug or significantly impair the ability to adhere to PrEP.
* Suspected sensitivity or allergy to the study drug or any of its components.
* Currently using an essential product or medication that interacts with the study drug such as the following:

* ART (including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents)
* Agents with known nephrotoxic potential:

* aminoglycoside antibiotics (including gentamicin)
* IV amphotericin B
* cidofovir
* cisplatin
* foscarnet
* IV pentamidine
* IV vancomycin
* oral or IV gancyclovir
* other agents with significant nephrotoxic potential
* Drugs that slow renal excretion

* Probenecid
* Immune system modulators

* Systemic chemotherapeutic agents (i.e. cancer treatment medications)
* Ongoing systemic corticosteroids (with the exception of short courses of tapering steroid doses for asthma or other self- limited condition).
* Interleukin-2 (IL-2)
* Interferon (alpha, beta, or gamma)
* Other agent known to have a significant interaction with TDF or FTC
* Proteinuria 2+ or greater by urine dipstick
* Signs or symptoms suggestive of acute HIV infection
* Any other reason or condition that in the opinion of the investigator would interfere with participation, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes